Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1612
    -0.0071 (-0.61%)
     
  • GBP/USD

    1.2371
    -0.0068 (-0.54%)
     
  • Bitcoin GBP

    51,830.90
    +630.26 (+1.23%)
     
  • CMC Crypto 200

    1,383.81
    +71.19 (+5.43%)
     
  • S&P 500

    4,956.62
    -54.50 (-1.09%)
     
  • DOW

    37,922.51
    +147.13 (+0.39%)
     
  • CRUDE OIL

    83.27
    +0.54 (+0.65%)
     
  • GOLD FUTURES

    2,407.70
    +9.70 (+0.40%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

Venous Thromboembolism Therapeutic Market Research Report by Drug Class - Global Forecast to 2025 - Cumulative Impact of COVID-19

Venous Thromboembolism Therapeutic Market Research Report by Drug Class (Direct Thrombin Inhibitors, Factor XA Inhibitors, Heparin, and Vitamin K Antagonists) - Global Forecast to 2025 - Cumulative Impact of COVID-19

New York, May 04, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Venous Thromboembolism Therapeutic Market Research Report by Drug Class - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05911850/?utm_source=GNW

Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Venous Thromboembolism Therapeutic Market is expected to grow from USD 2,045.35 Million in 2020 to USD 2,586.89 Million by the end of 2025.
2. The Global Venous Thromboembolism Therapeutic Market is expected to grow from EUR 1,793.40 Million in 2020 to EUR 2,268.23 Million by the end of 2025.
3. The Global Venous Thromboembolism Therapeutic Market is expected to grow from GBP 1,594.34 Million in 2020 to GBP 2,016.46 Million by the end of 2025.
4. The Global Venous Thromboembolism Therapeutic Market is expected to grow from JPY 218,291.12 Million in 2020 to JPY 276,087.01 Million by the end of 2025.
5. The Global Venous Thromboembolism Therapeutic Market is expected to grow from AUD 2,970.12 Million in 2020 to AUD 3,756.51 Million by the end of 2025.

Market Segmentation & Coverage:
This research report categorizes the Venous Thromboembolism Therapeutic to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug Class, the Venous Thromboembolism Therapeutic Market studied across Direct Thrombin Inhibitors, Factor XA Inhibitors, Heparin, and Vitamin K Antagonists.

Based on Geography, the Venous Thromboembolism Therapeutic Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Venous Thromboembolism Therapeutic Market including Abbott Laboratories Ltd, AngioDynamics Inc., Argon Medical Devices, Inc., Arjo AB, Astellas Pharma Inc., Bayer AG, Bio Compression Systems, Inc., BioInvent International AB, Bioinvent International AB, Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Company, Cardinal Health, Inc., Cook Medical Inc, Daiichi Sankyo Inc, eXIthera Pharmaceuticals LLC, Johnson & Johnson, Koninklijke Philips N.V., Medtronic PLC, Merck KGaA, Sanofi SA, Stryker Corporation, and Teleflex Inc..

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Venous Thromboembolism Therapeutic Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Venous Thromboembolism Therapeutic Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Venous Thromboembolism Therapeutic Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Venous Thromboembolism Therapeutic Market?
4. What is the competitive strategic window for opportunities in the Global Venous Thromboembolism Therapeutic Market?
5. What are the technology trends and regulatory frameworks in the Global Venous Thromboembolism Therapeutic Market?
6. What are the modes and strategic moves considered suitable for entering the Global Venous Thromboembolism Therapeutic Market?
Read the full report: https://www.reportlinker.com/p05911850/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001